Italia markets closed

Acacia Pharma Group plc (0PNT.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
1,4000-0,0620 (-4,24%)
Alla chiusura: 2:11PM GMT
Schermo intero
Chiusura precedente1,4620
Aperto1,4000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,4000 - 1,4000
Intervallo di 52 settimane1,4000 - 1,4000
Volume1
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,97
Rapporto PE (ttm)N/D
EPS (ttm)-0,4730
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A4,40
  • GlobeNewswire

    Acacia Pharma to Present at the Jefferies London Healthcare Conference

    Cambridge, UK and Indianapolis, US – 10 November 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), is pleased to announce that its Chief Executive Officer, Mike Bolinder will present at the Jefferies London Healthcare Conference 2021 on Tuesday, 16 November 2021. The presentation will begin at 09:20 GMT / 10.20 CET and a live video webcast will be available to registered conference attendees. The link to the webcast is available here. A replay will a

  • GlobeNewswire

    Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia Pharma Group plc Barhemsys® and Byfavo® launches continue to show strong progress gaining formulary access in 107 additional accounts over the past 3 monthsFor Barhemsys – 260 accounts on formulary with >80% win rate to date and well on track to meet annual formulary goal (300 accounts) by year endFor Byfavo – 95 accounts on formulary with >90% win rate to date, and

  • GlobeNewswire

    Acacia Pharma Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 September 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announce